PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The pharmaceutical company Myovant Sciences has bolstered its management with four new hires. Among them is a new chief medical officer. The company is also increasing its regulatory competences.
Juan Camilo Arjona Ferreira is the new chief medical officer at Myovant, announced the company in a statement. As vice-president of the Japanese pharma company Shionogi, he was responsible for the clinical development programme in the USA. Before that, he headed clinical development in women’s health products at Merck.
Also strengthening Myovant’s executive team is Teresa Perney, who joins as vice-president of regulatory affairs and quality assurance. She brings with her experience at pharmaceutical firms including Pfizer, Roche and Genentech.
Myovant’s lead compound is Relugolix, which recently produced positive results in clinical trials on the uterine disorder endometriosis. The compound is also to enter a phase 3 clinical trial on the treatment of prostate cancer.
Completing the new executive hires are Matthew Lang and Andria Langenberg. The former vice-president of Gilead Sciences, Lang was responsible for different areas in the litigation department. At Myovant, he will be general counsel and corporate secretary. Langenberg has decades of experience in drug development, most recently at Medivation. She joins Myovant as head of drug safety and pharmacovigilance.
Myovant president and CEO, Lynn Seely, highlighted the proven leadership qualities of the new employees, explaining that they would support the company’s development of innovative drugs for women’s health and endocrine diseases.